Richter syndrome (RS) is defined as the occurrence of an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL), in a patient with prior or concomitant chronic lymphocytic leukemia (CLL). RS is estimated to occur in 0.5-1 % per year and is associated with adverse outcome. In the vast majority of patients (80 %), RS is clonally related to the prior CLL. Those with unrelated RS appear to have better outcome. The therapeutic approach is based on those of de novo DLBCL or HL. However, even with modern immunochemotherapy regimens, response rate remains low. In eligible patients with related RS, a consolidation by autologous or allogeneic stem-cell transplantation must be proposed. Combinations including therapies targeting BCR or BCL2 and effective in CLL are currently being evaluated in RS. Novels immunotherapies could be promising approaches based on preliminary results.
Keywords: Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Leucémie lymphoïde chronique; Lymphoid neoplasm; Lymphome B diffus à grandes cellules; Néoplasie lymphoïde; Richter syndrome; Syndrome de Richter.
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.